Taiwanese scientists found that modification of a protein could be the cause of health issues such as hair loss and osteoporosis. Scientists came to this conclusion after studying results of a research conducted on mice.
A mice that showed symptoms of osteoporosis; severe hair loss; cachexia and amyloidosis, was having defective attachment of proteins. Such process of attachment is known as Palmitoylation in medical language.
The palmitoylation is the process where attachment takes place between fatty acid and proteins at molecular level. Researchers noticed that ZDHHC 13 gene caused such faulty palmitoylation which eventually lead to hair loss and osteoporosis and other protein based diseases.
More study on that mice model would be helpful for further research and development of possible hair loss drugs and osteoporosis drugs. Currently there is only one FDA approved drug, Propecia, to treat alopecia in male and no drug for female hair loss.
Scientists are hopeful to prevent defective attachment by identifying proteins that are being targeted by ZDHHC 13.
The outcome of study is believed to be first step towards proper understanding of molecular attachments between proteins in alopecia and osteoporosis patients.
Result of study was published in June 10 edition of international scientific journal PLoS Genetics by Chen Yuan-tsong and Jeffrey Yen. Chen Yuan-tson is director of Academia Sinica's Institute of Biomedical Sciences.
A mice that showed symptoms of osteoporosis; severe hair loss; cachexia and amyloidosis, was having defective attachment of proteins. Such process of attachment is known as Palmitoylation in medical language.
The palmitoylation is the process where attachment takes place between fatty acid and proteins at molecular level. Researchers noticed that ZDHHC 13 gene caused such faulty palmitoylation which eventually lead to hair loss and osteoporosis and other protein based diseases.
More study on that mice model would be helpful for further research and development of possible hair loss drugs and osteoporosis drugs. Currently there is only one FDA approved drug, Propecia, to treat alopecia in male and no drug for female hair loss.
Scientists are hopeful to prevent defective attachment by identifying proteins that are being targeted by ZDHHC 13.
The outcome of study is believed to be first step towards proper understanding of molecular attachments between proteins in alopecia and osteoporosis patients.
Result of study was published in June 10 edition of international scientific journal PLoS Genetics by Chen Yuan-tsong and Jeffrey Yen. Chen Yuan-tson is director of Academia Sinica's Institute of Biomedical Sciences.
No comments:
Post a Comment